Cybin's Acquisition Of Small Pharma Approved By Canadian Supreme Court

Short-acting psychedelics biotech Small Pharma Inc. DMTTF has obtained a final order from the Supreme Court of British Columbia approving the announced plan of arrangement, under Division 5 of Part 9 of BC’s Business Corporations Act, by which clinical-stage biotech firm Cybin Inc. CYBN is set to acquire all the former’s issued and outstanding securities in an all-share transaction.

See Also: Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

With this approval and both companies’ shareholder confirmations and pending satisfaction or waiver of customary closing conditions -including final approval by the TSX Venture Exchange, where Small Pharma trades,- the anticipated effective date for the arrangement’s closing is on or about October 23, 2023.

Upon the arrangement’s completion, Small Pharma’s common shares will be delisted from the TSXV and removed from the OTCQB Venture Market, with the company ceasing to be a reporting issuer in Canada.

See Also: Psychedelics Firm Optimind Pharma Sustains Growth Plan Rollout With New Acquisition

Did you miss the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth. Join Benzinga PotProfits. Benefit from Michael Berger’s sharp analysis, revealing top cannabis stock opportunities and timely updates. Experience the potential of 10%+ returns in just 90 days. Our 4.5-star Marketfy rating speaks volumes. Secure your position in this booming sector with a 30-day money-back guarantee. The time to invest is now before everyone else realizes it. Secure your profits with Benzinga. Click here now to learn more.

Photo: Benzinga edit with photo by Zita and Canadastock on Shutterstock.